{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/phase-i-trials-autoimmune-diseases-review-0#webpage",
"url": "https://www.fortrea.com/insights/phase-i-trials-autoimmune-diseases-review-0",
"name": "Phase I trials in autoimmune diseases review",
"description": "Explore this Fortrea white paper on autoimmune Phase I trials and discover how early clinical development strategies are evolving to support safer, more efficient autoimmune drug development across complex immune-mediated diseases. The white paper examines key considerations for early-phase autoimmune clinical trials, including translational autoimmune research, biomarker integration, immune pathway analysis, dose escalation strategies, pharmacodynamic assessment, and immune-mediated safety monitoring. Learn how biomarker-driven development models, patient stratification methodologies, translational immunology approaches, and optimized operational planning can improve autoimmune clinical trial execution, strengthen early safety evaluation, accelerate investigational therapy development, and support more informed decision-making across modern autoimmune research programs."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Phase I trials in autoimmune diseases review",
"item": "https://www.fortrea.com/insights/phase-i-trials-autoimmune-diseases-review-0"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/phase-i-trials-autoimmune-diseases-review-0#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/phase-i-trials-autoimmune-diseases-review-0#webpage"
},
"headline": "Autoimmune Phase I Trials, Biomarkers & Early Clinical Development Strategies | Fortrea White Paper",
"description": "Explore this Fortrea white paper on autoimmune Phase I trials and discover how early clinical development strategies are evolving to support safer, more efficient autoimmune drug development across complex immune-mediated diseases. The white paper examines key considerations for early-phase autoimmune clinical trials, including translational autoimmune research, biomarker integration, immune pathway analysis, dose escalation strategies, pharmacodynamic assessment, and immune-mediated safety monitoring. Learn how biomarker-driven development models, patient stratification methodologies, translational immunology approaches, and optimized operational planning can improve autoimmune clinical trial execution, strengthen early safety evaluation, accelerate investigational therapy development, and support more informed decision-making across modern autoimmune research programs.",
"genre": "White Paper",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-11-26",
"dateModified": "2025-11-26",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-11/autoimmune-phase-1-trials-review.pdf",
"encodingFormat": "application/pdf"
}
}
]
}